Navigation Links
Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
Date:3/20/2012

WELWYN GARDEN CITY, England and BOSTON, Massachusetts, March 20, 2012 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery company, announces that an operating company of Shire PLC (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development. Adenosine A2A is a G-protein coupled receptor (GPCR) involved in the regulation of dopaminergic pathways in the brain. Inhibition of the A2A receptor is a validated mechanism in the treatment of CNS disorders.

Under the terms of the agreement Heptares grants Shire an exclusive licence to worldwide development and commercial rights to A2Aantagonists discovered by Heptares. Heptares receives upfront option grant and exercise payments and is also eligible to receive future development and commercial milestone payments up to US$190 million plus royalties on product sales. Further terms of the agreement are not being disclosed.

Jeff Jonas, Senior Vice President, Research & Development, Specialty Pharmaceuticals and Regenerative Medicine, Shire, said:  "Shire is continuously in search of innovations that have the potential to help us develop well differentiated medicines that will bring value to patients. This agreement with Heptares is a reflection of our growth strategy of investing and focusing on highly targeted drug discovery platforms. We are impressed with the novelty and quality of the A2A antagonist leads generated by Heptares, resulting from what we believe to be the first time a structure-based drug discovery approach has been applied from the beginning to a GPCR drug target.  We look forward to a fruitful partnership with Heptares and to advancing the programme for the benefit of patients suffering from CNS disorders."

"The exercise of this option and initiation of the worldwide licensing agreement with Shire, one of the world's leading CNS specialty pharmaceutical companies, is an outstanding achievement for Heptares," said Malcolm Weir, CEO of Heptares. "The A2A programme is the most advanced example of the Heptares drug discovery platform, and highlights our ability to deliver fundamentally novel chemotypes as a basis for first-in-class and best-in-class medicines addressing a broad range of diseases."

The Heptares A2A programme reflects a new approach to this GPCR target. Recently published papers (refs 1-3) describe how Heptares technology was used to stabilise the A2A receptor, enabling the application for the first time of structure-based drug discovery (SBDD) techniques including Biophysical Mapping™, fragment screening and x-ray crystallography to the receptor. The advanced knowledge of the target generated by this approach enabled Heptares scientists to discover entirely new types of chemical structures for inhibiting the A2A receptor, potentially possessing best-in-class drug-like characteristics, a radical advance after decades of largely unsuccessful medicinal chemistry.

About Heptares Therapeutics

Heptares discovers and develops new medicines targeting GPCRs (G-protein-coupled receptors), a super-family of drug targets linked to a wide range of human diseases.  We have established R&D collaborations with Shire, Takeda, AstraZeneca, MedImmune and Novartis Option Fund, and have raised $40M in venture financing from MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures.  Heptares is an industry pioneer in GPCR structure-based drug design and has built a unique capability for discovering novel molecules that modulate historically undruggable or challenging GPCRs. Our integrated discovery platform includes proprietary technologies for engineering stabilised GPCRs in their natural pharmacological conformations, identifying previously unknown chemistries for GPCR protein-drug interactions, and deploying advanced fragment-based approaches to GPCR target space for the first time. Using this approach, we are generating a broad pipeline of drug candidates for serious CNS and metabolic disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, autism, anxiety & depression, chronic insomnia, addiction and diabetes.  For more information, please visit http://www.heptares.com.

References

  1. Langmead, C. et al. (2012) J. Med. Chem. DOI: 10.1021/jm201455y. Published online: January 17, 2012
  2. Congreve, M. et al. (2012) J. Med. Chem. DOI: 10.1021/jm201376w. Published online: January 5, 2012
  3. Zhukov, A. et al. (2012) J. Med. Chem., 2011, 54 (13), pp 4312-4323

Contact Information

Citigate DeweRogerson (for Heptares)
Mark Swallow, Chris Gardner
+1 857-222-4586
dan.grau@heptares.com

+44 (0)20-7282-2948
mark.swallow@citigatedr.co.uk

Heptares Therapeutics Ltd

Malcolm Weir, Chief Executive Officer (UK)
+44 (0)1707-358-629
malcolm.weir@heptares.com

Dan Grau, President (USA)
+1-857-222-4586
dan.grau@heptares.com



'/>"/>
SOURCE Heptares Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oxygen Healthcare (O2h) Announces Expanded Chemistry Collaboration With Heptares Therapeutics
2. Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h)
3. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
4. Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
5. NSF CAREER grants support ocean energy, microforming, computer planning
6. Maryland Stem Cell Research Commission Announces New Program for Pre-Clinical and Clinical Research Grants
7. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
8. Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry
9. Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock
10. FDA Grants Fast Track Designation to Tioga Pharmaceuticals Asimadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
11. FDA Grants Fast Track Designation to Bayers Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... MD (PRWEB) , ... April 27, 2016 , ... ... Greg Lamka, PhD to its Scientific Advisory Board. Dr. Lamka will assist PathSensors ... plant pathogen detection. , PathSensors deploys the CANARY® test platform for the ...
(Date:4/27/2016)... ... ... Global Stem Cells Group CEO Benito Novas announced that Duncan Ross, Ph.D. ... Labs in Miami. , In 2004, Ross received his Ph.D. in Immunology from the ... the suppression of graft vs. host disease (GVHD) under UM Professor Robert Levy Ph.D. ...
(Date:4/27/2016)... -- MedDay, a biotechnology company focused on the ... Catherine Moukheibir as Chairman of its Board of Directors. ... Garaud , who contributed to the rapid development of the ... Catherine started her career in strategy consulting and investment banking ... .  She held C-Suite level roles in some of ...
(Date:4/26/2016)... ... 27, 2016 , ... Cameron Cushman has joined ... in the firm’s Intellectual Property practice group. , Clients turn to Cushman for ... has an electrical engineering and computer engineering background, and experience in the medical ...
Breaking Biology Technology:
(Date:3/15/2016)... , March 15, 2016 ... report published by Transparency Market Research "Digital Door Lock Systems ... Forecast 2015 - 2023," the global digital door lock systems ... Mn in 2014 and is forecast to grow at a ... of micro, small and medium enterprises (MSMEs) across the world ...
(Date:3/14/2016)... http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ( ... --> DERMALOG, le leader de l,innovation ... d,empreintes digitales pour l,enregistrement des réfugiés en Allemagne. ... produire des cartes d,identité aux réfugiés. DERMALOG dévoilera ...
(Date:3/10/2016)... , March 10, 2016 ... new market research report "Identity and Access Management Market ... Audit, Compliance, and Governance), by Organization Size, by Deployment, ... 2020", published by MarketsandMarkets, The market is estimated to ... 12.78 Billion by 2020, at a Compound Annual Growth ...
Breaking Biology News(10 mins):